Biosimilar Development News

  1. Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States

    Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).

  2. Uptake Of Biosimilars In The EU5 Blunts Share Of AbbVie's Humira And Merck's Remicade In The Crohn's Disease And Ulcerative Colitis Markets, While A Black Cloud Of Safety Concerns Still Follows Pfizer's Xeljanz

    According to the latest report published as part of Spherix's RealTime Dynamix™: Inflammatory Bowel Disease (EU) service, EU5 gastroenterologists (n=255) report rapid uptake of adalimumab biosimilars for the treatment of both Crohn's disease and ulcerative colitis (UC), with the biosimilar brands accounting for roughly one-tenth of biologic/JAK share for each market.

  3. New Issue Brief: Increased Use Of Biosimilars Could Bring Billions In Savings For Patients, Providers, Taxpayers

    Biosimilars have the potential to realize billions in savings for the health care system if reforms are enacted to incent their market share to grow, according to a new issue brief issued today by the Center for Medical Economics and Innovation at the California-based, free-market think tank, the Pacific Research Institute.

  4. New Analysis Confirms Increased Use Of Biosimilars Can Save U.S. Up to $71B Over A Decade

    Following the release of the Pacific Research Institute’s (PRI) latest issue brief entitled “Incenting Competition to Reduce Drug Spending: The Biosimilar Opportunity” by Wayne Winegarden, the Biosimilars Forum President, Juliana Reed, recently issued the following statement:

  5. Mylan Launches In Spain Hulio, Adalimumab Biosimilar, For Autoimmune Diseases

    Mylan launches Hulio (adalimumab), its first biosimilar in Spain. Adalimumab is an injectable biologic drug that inhibits Tumor Necrosis Factor (TNF) and is indicated for the treatment of a variety of rheumatic, dermatological and gastroenterological autoimmune diseases.

  6. Prestige BioPharma Releases Positive Results From Phase I Study Of HD204, Biosimilar Candidate To Bevacizumab

    Prestige BioPharma (herein, Prestige) announced positive results from a Phase I clinical trial (SAMSON-I) evaluating the pharmacokinetics (PK), safety and immunogenicity of biosimilar candidate HD204 to Avastin (bevacizumab).

  7. Prestige Biopharma And Pharmapark Announce License And Supply Agreement To Commercialize Prestige's Trastuzumab Biosimilar In The Russian Federation

    Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in the Russian Federation.

  8. Mundipharma Announces Exclusive License And Supply Agreement With Prestige Biopharma For Tuznue (HD201)

    Mundipharma has entered into an exclusive license and supply agreement with Prestige Biopharma for Tuznue, a trastuzumab biosimilar treatment.The agreement will enable the Mundipharma network to distribute, market and sell Tuznue in selected European countries following marketing authorisation, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria.

  9. Susan G. Komen Seeks To Educate Patients About Biosimilars

    Susan G. Komen, the world’s leading breast cancer organization, is seeking to educate patients about a new wave of alternative drugs, known as biosimilars, that will soon hit the market to treat HER2-positive breast cancer.

  10. Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled Syringes

    Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date.